To match innovators with a task force of experts to develop commercially-viable products and services with the greatest potential for societal and economic impact in Europe this time European Institute of Innovation and Technology (EIT Health) joined forces with Amgen, Bayer, Beiersdorf AG, and Boehringer Ingelheim.
AMGEN, one of the world’s leading biotechnology companies, aimed at finding the solution to create a standardized procedure for post-MI patients after discharge, pointing out that preventing myocardial infarction (MI) in a population at risk and in patients who have already experienced an MI episode is extremely important.
Particularly, AMGEN was looking for a predictive analytics tool to identify very high-risk patients and a procedure/tool which will provide holistic support to post-MI patients after discharge.
Cardiolyse provides exactly the platform for accurate and complex remote cardiac patients monitoring with the proprietary algorithms on heart failure risk stratification.
We're excited by the delivered innovation and entrepreneurship workshops and are looking forward to furthering program collaborations!
